In this webinar, our panel of Africa-based researchers discuss the strong clinical research foundation, the community-centered approach and increasing regulatory harmonization in Africa. Watch to learn about the continent’s population diversity, expanding therapeutic area expertise and long-standing stakeholder engagement.
Our broad expertise, end-to-end services and ability to begin immediate collaboration with government, commercial and academic partners in more than 60 countries make us uniquely positioned to support the COVID-19 response. We address emerging pandemics, epidemics and outbreaks with expertise that supports health and research efforts globally. We are experienced in addressing the complex aspects of infectious diseases — from infection prevention and control to clinical research on diagnostics, vaccines and treatment.
FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
In the fall of 2021, a small team from FHI Clinical headed to Liberia to meet the FHI Clinical PREVAIL network team. Watch this video to learn more about the purpose and goals of their trip.
We believe that building and sustaining research capacity, particularly in resource-limited, research-naïve areas, will help address public health issues around the globe. Watch the video to learn how our teams support sites to develop sustainable research capacity and produce high-quality study data. In addition, we work with regional institutions to establish networks of research-ready sites that focus on local health and research priorities.
The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network was established through a partnership between local Liberian and international partners, including the U.S. National Institutes of Health, World Health Organization and FHI Clinical, to provide sustainable research infrastructure to address diseases of public health importance.
The study team maintained a 91% retention rate in a study of a Chikungunya virus (CHIKV) vaccine, despite study disruptions due to natural disasters, including Hurricane Maria, and political unrest near the sites in five Caribbean countries in a CHIKV endemic region.
Since 1976, Ebola virus disease outbreaks have primarily occurred in eleven countries: Democratic Republic of the Congo, Gabon, Guinea, Liberia, Mali, Nigeria, Republic of Congo, Sierra Leone, Sudan and Uganda. Although it is generally rare, it is often fatal, with death rates ranging from 25 to 90% in past outbreaks (average case fatality rate, 50%). No treatment or vaccine is currently approved, but there are several promising vaccines and treatments under development.
Outbreaks large and small require rapid, coordinated responses. In this e-book, we describe eight considerations for outbreak responses, based on the collective experience of our experts.
Collaborative relationships ensure site sustainability. Keeping a site functional, even in slow times, preserves investment in human and equipment resources and ensures the site is ready to conduct quality research as soon as there is a need.